ACTG1P17: A Potential Drug Target and Biomarker for Glioblastoma

Target Name: ACTG1P17

NCBI ID: G283693

ACTG1P17

Other Name(s): Actin gamma 1 pseudogene 17 | actin gamma 1 pseudogene 17

ACTG1P17: A Potential Drug Target and Biomarker for Glioblastoma

Glioblastoma is one of the most aggressive forms of cancer, with a high incidence and poor prognosis. Despite advances in surgical and radiation treatments, the survival rate for glioblastoma remains dismal, and the disease is often associated with poor quality of life and recurrence. Therefore, there is a need for new therapeutic approaches to treat glioblastoma.

ACTG1P17, a gene encoding for actinin gamma 1 (ACTN1), has been identified as a potential drug target and biomarker for glioblastoma. In this article, we will discuss the biology of ACTN1, its potential as a drug target, and its potential as a biomarker for glioblastoma.

Biography of ACTN1

Actinin gamma 1 (ACTN1) is a protein that is expressed in many tissues, including brain, heart, and skeletal muscles. It is a member of the actinin gene family, which is characterized by the presence of a unique amino acid sequence, known as actinin alpha-helices, in the extracellular region of the protein.

ACTN1 has been shown to play a role in various physiological processes, including cell signaling, cytoskeletal organization, and tissue mechanics. It is involved in the regulation of cell adhesion, cell migration, and the formation of blood vessels.

In addition to its role in cell biology, ACTN1 has also been shown to be involved in the development and progression of certain diseases, including cancer. For example, studies have shown that high levels of ACTN1 have been associated with the development of various types of cancer, including breast, ovarian, and prostate cancer.

Potential Drug Target

The potential drug target for ACTN1 is its role in cell signaling and the regulation of cell adhesion. Activated actinin gamma 1 (ACTN1) has been shown to play a role in the regulation of cell adhesion by interacting with the protein cadherin. This interaction between ACTN1 and cadherin has been shown to contribute to the regulation of cell adhesion and the development of certain diseases, including cancer.

In addition to its role in cell adhesion, ACTN1 has also been shown to play a role in the regulation of cell migration. This is thought to contribute to the development of certain types of cancer, including metastatic cancer.

Potential Biomarker

Actinin gamma 1 (ACTN1) has also been shown to be a potential biomarker for several types of cancer, including glioblastoma. High levels of ACTN1 have been associated with the development of glioblastoma, and therapeutic approaches that target ACTN1 have been shown to be effective in treating this type of cancer.

In addition to its potential as a drug target, ACTN1 has also been shown to be a potential biomarker for glioblastoma by its expression in the tumor cells. Studies have shown that the expression of ACTN1 is associated with the development of certain types of cancer, including glioblastoma. This suggests that ACTN1 may be a useful biomarker for the diagnosis and prognosis of certain types of cancer, including glioblastoma.

Conclusion

ACTG1P17, a gene encoding for actinin gamma 1 (ACTN1), has been identified as a potential drug target and biomarker for glioblastoma. Its role in cell signaling and the regulation of cell adhesion, as well as its potential as a biomarker for the diagnosis and prognosis of certain types of cancer, make it an attractive target for therapeutic approaches. Further studies are needed to

Protein Name: Actin Gamma 1 Pseudogene 17

The "ACTG1P17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTG1P17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets